dc.contributor.author |
Scott, Terence Peter
|
|
dc.contributor.author |
Nel, Louis Hendrik
|
|
dc.date.accessioned |
2022-04-11T09:48:06Z |
|
dc.date.available |
2022-04-11T09:48:06Z |
|
dc.date.issued |
2021-05 |
|
dc.description.abstract |
If the goal of eliminating dog-mediated human rabies by 2030 is to be achieved, effective
mass dog vaccination needs to be complemented by effective prophylaxis for individuals exposed
to rabies. Aptamers and short-interfering RNAs (siRNAs) have been successful in therapeutics,
but few studies have investigated their potential as rabies therapeutics. In this study, siRNAs and
aptamers—using a novel selection method—were developed and tested against rabies virus (RABV)
in a post-infection (p.i.) scenario. Multiple means of delivery were tested for siRNAs, including
the use of Lipofectamine and conjugation with the developed aptamers. One siRNA (N53) resulted
in an 80.13% reduction in viral RNA, while aptamer UPRET 2.03 demonstrated a 61.3% reduction
when used alone at 2 h p.i. At 24 h p.i., chimera UPRET 2.03-N8 (aptamer-siRNA) resulted in a 36.5%
inhibition of viral replication. To our knowledge, this is the first study using siRNAs or aptamers
that (1) demonstrated significant inhibition of RABV using an aptamer, (2) tested Lipofectamine
RNAi-Max as a means for delivery, and (3) produced significant RABV inhibition at 24 h p.i. This
study serves as a proof-of-concept to potentially use aptamers and siRNAs as rabies immunoglobulin
(RIG) replacements or therapeutic options for RABV and provides strong evidence towards their
further investigation. |
en_US |
dc.description.department |
Biochemistry |
en_US |
dc.description.department |
Genetics |
en_US |
dc.description.department |
Microbiology and Plant Pathology |
en_US |
dc.description.librarian |
pm2021 |
en_US |
dc.description.sponsorship |
Poliomyelitis Research Fund;
University of Pretoria under the Institutional Research Theme (IRT);
National Research Foundation (NRF). |
en_US |
dc.description.uri |
http://www.mdpi.com/journal/viruses |
en_US |
dc.identifier.citation |
Scott, T.P.; Nel, L.H. Rabies
Prophylactic and Treatment Options:
An In Vitro Study of siRNA- and
Aptamer-Based Therapeutics. Viruses
2021, 13, 881. https://doi.org/10.3390/v13050881. |
en_US |
dc.identifier.issn |
1999-4915 (online) |
|
dc.identifier.other |
10.3390/v13050881 |
|
dc.identifier.uri |
https://repository.up.ac.za/handle/2263/84860 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
MDPI |
en_US |
dc.rights |
© 2021 by the authors.
Licensee: MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license. |
en_US |
dc.subject |
Aptamer |
en_US |
dc.subject |
Rabies |
en_US |
dc.subject |
Post-exposure prophylaxis |
en_US |
dc.subject |
Treatment |
en_US |
dc.subject |
Rabies immunoglobulin |
en_US |
dc.subject |
Lyssavirus |
en_US |
dc.subject |
Rabies lyssavirus (RABV) |
en_US |
dc.subject |
Short-interfering RNAs (siRNAs) |
en_US |
dc.title |
Rabies prophylactic and treatment options : an in vitro study of siRNA- and aptamer-based therapeutics |
en_US |
dc.type |
Article |
en_US |